Kanabo Group Plc (LON: KNB)

Kanabo Group Plc (LON: KNB) is an R&D company currently selling a range of THC-Free Retail CBD Products in the Primary Markets and is in the process of developing Medical Cannabis Products. The company’s core strategy is to increase revenues from the sale of its Retail CBD Products in the wellness sector and to grow the Kanabo brand through its marketing initiatives.

Kanabo Group Plc (LON: KNB) Kanabo is currently undertaking a pilot scheme, which will continue for a period of up to 3 months following Admission. The purpose of the Pilot is to measure a number of key performance indicators in relation to the sale of its Retail CBD Products, including consumer preferences, demands for Retail CBD Products, the effectiveness of the supply chain and compliance with quality controls.

The Company has had a 40% customer retention rate since the inception of the Pilot. The second phase will be aimed at delivering growth in sales of Kanabo’s Retail CBD Products.

Kanabo’s future strategy involves continued research and development activities to develop a range of Unlicensed Medical Cannabis Oils, which will be sold alongside its vaporisation device, the VapePod Medical. It is intended that Unlicensed Medical Cannabis Oils will be sold as unlicensed medicines in the UK and Germany.

www.kanabogroup.com LON: KNB

Kanabo Group signs term sheet to acquire Materia’s European businesses

Kanabo Group announces initial commercial scale production

Kanabo Group signs new EU GMP CBD manufacturing agreement

Leave a Reply

Your email address will not be published. Required fields are marked *